Download Files:
CU06-1004
$500 – $4,800
Products Details
Product Description
– CU06-1004 (Sac-1004) is an orally active endothelial dysfunction blocker. CU06-1004 ameliorates endothelial dysfunction by inhibiting hyperpermeability and inflammation, and is potent in inhibiting vascular leakage and inflammation in various animal models, such as diabetic retinopathy, stroke, cancer, and inflammatory bowel disease. CU06-1004 ameliorates CDAA-induced mouse model of NASH. CU06-1004 also improves cardiac function[1][2][3].
Web ID
– HY-155946
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Molecular Formula
– C37H54O8
References
– [1]Zhang H, et al. CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury. Exp Mol Med. 2022 Jan;54(1):23-34.|[2]Bae CR, et al. Correction: The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice. PLoS One. 2021 Apr 5;16(4):e0249747.|[3]Kim Y, et al. Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury. J Inflamm (Lond). 2023 Apr 6;20(1):13.
CAS Number
– 1296734-08-1
Molecular Weight
– 626.82
Compound Purity
– 99.94
SMILES
– C[C@@]12[C@](CC[C@@H]2/C(C)=C/CCCC(OC)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)OC5O[C@@H]([C@H](C=C5)OC(C)=O)COC(C)=O)=CC3)C
Clinical Information
– No Development Reported
Research Area
– Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– Others
Pathway
– Others
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
